Navigation Links
Pharmasset to Present at Two Upcoming Investor Conferences
Date:11/10/2008

he treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Richard E. T. Smith, Ph.D.

VP, Investor Relations and Corporate Communications

richard.smith@pharmasset.com

Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
2. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
5. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
6. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
7. Pharmasset Joins Russell 3000 Index
8. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
9. Pharmasset Selected to Join the NASDAQ Biotechnology Index
10. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
11. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic Biologics, ... developing novel anti-infective biologic and drug programs targeting ... announced today that its novel C. difficile ... 54 th Interscience Conference on Antimicrobial Agents ... Washington D.C. Synthetic Biologics, ...
(Date:8/18/2014)... -- A new therapy developed by researchers at ... of Medicine and Columbia University Medical Center (CUMC) ... cardiovascular disease treatment. , The researchers demonstrated ... therapy could selectively inhibit blood vessel re-narrowing and ... using a balloon catheter to open narrowed or ...
(Date:8/18/2014)... unprecedented efficiency and data storage may someday ... electric polarizations to read and write digital ... data-driven technology. But ferroelectrics must first overcome ... curious habit of "forgetting" stored data. ... of Energy,s Brookhaven National Laboratory have discovered ...
(Date:8/18/2014)... 2014 TNI BioTech, Inc. (OTC-BB: TNIB) ("we" ... and marketing of innovative therapies for autoimmune diseases in ... a second notice of TNI BioTech,s annual meeting of ... Noreen Griffin , founder and CEO of TNI ... participation in the Annual Meeting. On behalf of our ...
Breaking Biology Technology:Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4
... N.C., Feb. 25 Attagene Inc., a,biotechnology ... analysis, announced today that one of the ... FACTORIAL(TM). In,advance online publication on Nature Methods, ... novel and remarkably consistent method for,simultaneously reporting ...
... 25 t2cure, a clinical,stage biopharmaceutical company developing ... today that it has appointed,Dr. Petra Rueck Head ... have Petra join our company", said Manfred Ruediger,CEO ... project,management will be of critical importance to t2cure ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) announced today that ... President of ImClone Systems Incorporated, will,join its Board of ... size of its Board from six to seven directors., ... Board of Directors. He brings,tremendous knowledge and expertise within ...
Cached Biology Technology:Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 2Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 3Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations 2Eric K. Rowinsky Joins ADVENTRX Board of Directors 2Eric K. Rowinsky Joins ADVENTRX Board of Directors 3Eric K. Rowinsky Joins ADVENTRX Board of Directors 4
(Date:8/19/2014)... fish purchased at retail seafood counters in 10 ... can expose consumers to unexpectedly high levels of ... falsely present a fish of the same species, ... dangerous mislabeling offense, according to new research by ... labeling of seafood is essential to allow consumers ...
(Date:8/19/2014)... -- ( Aug. 19, 2014 ) -- Scientists at ... to pick up and transfer single cells using a ... slightly. They describe this engineering feat and preliminary test ... of the American Chemical Society . , "Studying single ... in current biomedical research," said nanomedicine department. faculty member ...
(Date:8/19/2014)... who has ever had a glass of fizzy soda ... air. But in a finding with wide industrial applications, ... some particles down into the liquid as well. , ... droplets, so we were surprised, and fascinated, to discover ... same process injected tiny oil droplets into the water," ...
Breaking Biology News(10 mins):Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Moving single cells around -- accurately and cheaply 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3
... Washington DC (February 11, 2010) While many adults consider ... to be obese teens, saddling them with Type-2 diabetes, elevated ... this month in the journal Clinical Pediatrics (published ... point" in obesity often occurs before two years of age, ...
... Sultan, assistant professor of aerospace and ocean engineering at Virginia ... learn he has received a National Science Foundation (NSF) Faculty ... list of more than 70 Virginia Tech CAREER award winners, ... of Engineering since the award was created in 1994. He ...
... modifications to proteins called histones, which are found in ... which DNA is wound, can be used to predict ... pancreatic cancer, a study by researchers at UCLA,s Jonsson ... two specific histone modifications in tumor cells of patients ...
Cached Biology News:2 years old -- a childhood obesity tipping point? 2Engineer studies tensional integrity of biological structures 2Engineer studies tensional integrity of biological structures 3Predicting prognosis and treatment response in a subset of pancreatic cancer patients 2Predicting prognosis and treatment response in a subset of pancreatic cancer patients 3